Clinical Trials Search
Clinical Trial 18428
Cancer Type: Thoracic
Interventions:Crizotinib; Erlotinib; Paraplatin (carboplatin); Tarceva (Erlotinib); Taxol (paclitaxel); Xalkori (Crizotinib); carboplatin; cisplatin; etoposide; paclitaxel
Study Type: Treatment
Phase of Study: Phase II
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to find out what effects, good and/or bad, one of the following treatments has on participants and their locally advanced, non-operable lung cancer with specific gene alterations (EGFR mutation or ALK rearrangement).
Primary Objective: To assess whether patients with unresectable local-regionally advanced NSCLC treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone. Secondary Objectives: To evaluate response rate; to assess toxicity; to assess overall survival; to correlate clinical outcomes with tumor molecular aberrations identified from deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available.